semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Neoplasms Histologically confirmed invasive breast cancer With axillary lymph node with thickened cortex Planned for sentinel lymph node biopsy or axillary clearance  Nodes ultrasonographically normal Nodes with hilar displacement  Palpable matted nodes
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ST-elevation Myocardial Infarction Multivessel Coronary Disease Age ≥ 18 years Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) Suitability for PCI from femoral or radial access Coronary anatomy suitable for complete coronary revascularization with Synergy® stent implantation Identifiable culprit lesion/artery At least one non-culprit coronary stenosis ≥ 70% in at least two projections, in a vessel with a lumen diameter ≥2.25 ≤5.75 mm, other than the culprit artery TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery Stable hemodynamics at the end of the culprit vessel revascularization  Inability to give informed consent Cardiogenic shock Prolonged resuscitation >10 min General unsuitability for PCI Need for emergency CABG Previous CABG Planned hybrid revascularization Coronary artery dissection Stent thrombosis Instent restenosis
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Post menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I III with no evidence of metastatic disease (M0) Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery Patient must be on one of AI (steroidal or non-steroidal) Patient must be able to complete a demographic and the MMAS questionnaires in English or Spanish  < 18 years old
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients must be female, at least 18 years of age Patients or their legally authorized representative must have signed and dated an informed consent form Patients must have at minimum, adequate samples of breast tissue available for use in this study Patients with a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion Patients with a diagnosis of atypical ductal hyperplasia, lobular cancer in situ or any preinvasive breast lesion Patients with ductal carcinoma in situ undergoing either lumpectomy and radiation or mastectomy Patients with a diagnosis of invasive ductal cancer  Male Patients under the age of 18 or over the age of 89 Patient desires not to participate in the study Inability to consent
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer all patients undergoing breast MRI  general contraindication to MRI -
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Metastatic Breast Cancer Age ≥ 18 years of age Female gender Biopsy proven diagnosis of breast cancer Stage IV disease diagnosed either by radiographic studies or biopsy ER+ by immunohistochemistry on primary and/or metastatic tissue biopsy (>10%) HER2 non-amplified (1+ or below by immunohistochemistry, and/or Her2 FISH <2 HER2-to-CEP17 ratio) Progressed on at least one prior line of endocrine therapy for metastatic disease Three or fewer prior endocrine-containing therapies for recurrent/metastatic disease Two or fewer prior lines of cytotoxic chemotherapy for recurrent/metastatic disease Plans to initiate 2nd, 3rd, or 4th line endocrine therapy for metastatic disease  < 18 years of age Tissue biopsies that support the presence of both ER+ and ER metastatic breast cancer in the same patient Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent Pregnant or lactating women
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Targeted Therapy HER2 Biliary Tract Cancer Esophageal Squamous Cell Carcinoma Colorectal Cancer Signed informed consent Male and female patients aged from 18 to 75 years Histologically confirmed Colorectal cancer,Esophagus squamous cell carcinoma, biliary tract cancer, and digestive system tumor beyond CRC and GC&GEJA with the following specifications genetic testing conformed KRAS/NRAS/BRAF all wild type for colorectal cancer Detection of a carcinoma with HER2 3+ (IHC) or HER2 2+ (IHC) with amplification proven by fluorescence in situ hybridization(FISH), silver in situ hybridization（SISH） or chromogenic in situ hybridization（CISH） using gastric cancer by an accredited local pathologist Relapse or metastatic diseases, at least one measurable lesion according to 1.1, anticipated survival ≥ 12 weeks ECOG Performance status 0-1 Patients who failed at least first line systemic therapy Adequate organ function as determined by the following laboratory results Absolute neutrophil count ≥1500 cells/mm3  Known hypersensitivity against treatment regimen Baseline left ventricular ejection fraction(LVEF) < 50% (measured by echocardiography or MUGA) Previous anti-her treatment Immune therapy, biological therapy or any participation in clinical trial in previous two weeks Surgery and not recovered in previous three weeks Clinical evidence of brain metastases, or uncontrolled epilepsy Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, New York Heart Association(NYHA) III-IV; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular heart disease; unstable angina pectoris, myocardial infarction or high risk uncontrollable arrhythmias Long term or high dose corticosteroids administration ( inhalation or short term oral administration for antiemesis and orexigenic is allowed)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Cancer Age 18 years or older Have documented or reported microscopic hematuria within 3 month of study enrollment Willing and able to give written informed consent  (participants must not) Have history of BCa History of previous cancer (excluding basal and squamous cell skin cancer) Have a known active urinary tract infection or urinary retention Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL) Have ureteral stents, nephrostomy tubes or bowel interposition Have recent genitourinary instrumentation (within 10 days prior to signing consent) Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Any patient with histologically confirmed newly diagnosed operable ER+, Her2 negative invasive carcinoma on diagnostic core biopsy that has a radiographic size ≥ 1.5 cm Histology has to be ductal, lobular or mixed Surgery date planned in the next 2-6 weeks Negative pregnancy test if of child baring potential Post-menopausal status verified by FSH and Estradiol (with 6 months of amenorrhea)  Previous treatment with endocrine therapy, chemotherapy or chest wall radiation within last 6 months Known metastatic or recurrent breast cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Invasive Breast Cancer Female; age ≥18 years Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II Clinically lymph node negative, confirmed by clinical exam and/or ultrasound imaging Estrogen and/or progesterone-receptor-positive tumor, defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines HER2/neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Pretreatment evaluations (minimum diagnostic workup) within 28 days prior to study Qualify for anti-endocrine treatment (per medical oncologist) Informed consent provided  American Joint Committee on Cancer (AJCC) clinical T4, N1-3 or M1, breast cancer Synchronous non-breast malignancy (exceptions non-melanomatous skin cancer, carcinoma in situ of the cervix) Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ) Men with breast cancer Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent Pregnant or lactating women
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chemotherapy-induced Neutropenia Cancer, Breast Age 18-65 Diagnosed breast cancer，received chemotherapy ECOG performance status 0 or 1 ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function normally, no Hemorrhagic tendency Leukocyte reduction occurred after chemotherapy,WBC≤3.0x109/L or ANC≤1.5x109/L No obvious abnormal ecg examination Cr，TBIL, AST, ALT≤1.5×ULN，no serious underlying disease Signed informed consent  Chemotherapy within past 4 weeks Uncontrolled inflammatory disease,axillary temperature≥38℃ Merging other malignant tumor Pregnancy or nursing status Participation in another clinical trial with and investigational product within 3 months prior to study entry Severe diabetes mellitus, or poor blood sugar controller Allergic disease or allergic constitution. History of protein allergy History of drug addiction and alcoholism Hematopoietic stem cell transplantation or organ transplantation Received antibiotic treatment within 72 hours before chemotherapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Invasive Breast Cancer Invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) Underwent computed tomography (CT) reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy (NAC) Attend the study voluntarily, sign the informed consent  Contradiction for adjuvant chemotherapy Contradiction for proceeding surgery
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Transitional Cell Carcinoma Capable of giving written informed consent Age ≥18 years Referral to haematuria clinic (gross or microscopic haematuria)  Inability to provide written informed consent Previous radiotherapy to the bladder (e.g. prostate cancer) Active urinary tract infection (Patients may be re-approached at later opportunity when urinary infection is cleared and haematuria persists) Current or planned treatment with neoadjuvant chemotherapy or radiotherapy Other known malignant condition, either active or in complete remission ≤5 years HIV, hepatitis C, or any other known communicable disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Breast Neoplasm Histologically proven invasive carcinoma of the breast One to three positive axillary lymph nodes (pN1) proven in pathologic specimen Prior breast-conserving surgery and post-operative adjuvant chemotherapy including taxane Administering adjuvant hormonal therapy in cases with hormone receptor-positive tumor Administering anti-HER2 therapy in cases with HER2-positive tumor  Metastases in supraclavicular or internal mammary lymph nodes Metastases in distant organs Neoadjuvant chemotherapy or hormone therapy before surgery Not receiving adjuvant anthracycline and taxane Bilateral breast cancer Previous history of radiotherapy of the ipsilateral breast or supraclavicular lymph nodes Prior history of other types of cancer, except thyroid cancer, carcinoma in situ of the cervix, or skin cancer
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  Breast Cancer The study will 30 women with early-stage breast cancer treated at general surgery department, Assuit University Hospitals For all patients an informed consent for their in the study including the use of images will be obtained Selection women with a pre-operative diagnosis (clinical examination, imaging and needle biopsy) of Tis, T1 and T2 tumours without extensive skin involvement  • contraindaction for general anesthesia Positive margin requiring mastectomy Insufficient remaining breast volume Diffuse microcalcifications Multicentric tumor? Inflammatory breast cancer Previous radiotherapy Concomitant disease ( Diabetes, smoking )
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women age 18 years or older Confirmed histologic diagnosis of operable HER2 overexpressing (ER<10%, PR<10%, and HER2 2+ or FISH amplified) OR triple negative (ER<10%, PR<10%, and HER2 0/1+ or 2+/FISH not amplified) OR ER positive invasive ductal or invasive lobular breast cancer including MSKCC pathology confirmation Operable breast cancer treated with NAC undergoing either breast conservation or total Mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a complete imaging response, which is defined as no residual tumor enhancement No indication of distant metastases (M0) Tumor site amenable to MRI guided biopsy as determined by the radiologist Definitive surgery being performed at MSKCC within within 0-60 days of completing NAC ECOG performance status score of 0 to ≤ 2 and or KPS performance status score of 80% to 100% Women of childbearing potential (WOCBP) must not be pregnant Women must not be breastfeeding Willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol  Medical history and concurrent disease Prior history of treated breast cancer Any underlying medical or psychiatric conditions, which in the opinion of the investigator, will make performing the study intervention hazardous or obscure the interpretation of the results Prohibited Treatments and/or Therapies Prior history of breast cancer surgery and/or radiotherapy